Developer docs
API playgroundTry for free, no card

Search company profiles

Syndex Bio

Full company profile

uuid000241i

Namestring
Syndex Bio
Legal namestring
Syndex Bio Limited
Websiteurl
syndex.bio
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Syndex Bio is a Cambridge, UK-based biotechnology company founded in 2022 that has developed mcPCR (methyl-copying PCR), a proprietary platform technology designed to preserve 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. Conventional PCR cannot copy epigenetic methylation marks; mcPCR uses proprietary methyl transferase enzymes to copy both the four-base genetic code and methylation modifications on newly synthesised strands, enabling analysis from limiting clinical samples including liquid biopsies. The platform supports both whole-genome and targeted workflows with a non-destructive process intended to integrate into downstream genomic and multi-omic analyses. Target applications include oncology testing and early cancer detection, residual disease and treatment monitoring, drug development and patient stratification, and chronic disease detection.

The company operates a B2B go-to-market targeting clinical laboratories, healthcare providers, and research institutions. Revenue is expected to come from one-time licences of the mcPCR platform and reagents, supplemented by professional services tied to clinical workflow development. The company has 17 employees, no disclosed paying customers, and publicly undisclosed pricing. Its founding team includes individuals credited with inventing and commercialising next-generation sequencing (NGS) technology.

In February 2026 Syndex Bio publicly launched the mcPCR platform at the AGBT General Meeting in Orlando and concurrently closed a $15.5 million oversubscribed seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. Concurrent with the financing, the company formed a board of directors that includes Gautam Kollu, former Chief Commercial Officer of Grail, signalling intent to build an enterprise commercial motion in molecular diagnostics. Syndex Bio is collaborating with undisclosed research groups to advance liquid biopsy applications and plans to compete alongside rivals such as Epinoma in early-stage cancer detection.

Short descriptiontext

Syndex Bio is a Cambridge, UK biotech startup developing mcPCR, a proprietary PCR-based platform that preserves DNA methylation patterns during amplification, targeting clinical laboratories and research institutions for applications in early cancer detection, liquid biopsy, and disease monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA methylation analysis, molecular diagnostics, PCR technology platform, liquid biopsy reagents, epigenetics research tools
Industry5 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1mcPCR platform and reagents
TypeOne Time License
Description

Revenue expected from selling mcPCR technology, reagents, and kits to clinical laboratories, healthcare providers, and research institutions for DNA methylation analysis applications including early cancer detection, disease monitoring, and clinical diagnostics.

genomeweb.com
2Clinical workflow development
TypeProfessional Services
Description

Developing clinical workflows and applications that will enable deployment of mcPCR technology in healthcare settings for oncology testing, residual disease monitoring, drug development, and chronic disease detection.

syndex.bio
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Syndex Bio develops and sells the proprietary mcPCR (methyl-copying PCR) platform, a biotechnology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. The platform enables high-fidelity copying of both epigenetic modifications and the underlying four-base genetic code, overcoming a fundamental 40-year limitation of conventional PCR. The company sells the technology along with reagents and kits to clinical laboratories, healthcare providers, and research institutions for applications including oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Earlier disease detection through sensitive methylation analysis from liquid biopsies
+2 more records
Product overview1 text field

Syndex Bio offers a single unified product platform: the mcPCR™ (methyl-copying PCR) platform. This proprietary technology is designed to preserve DNA methylation (5mC) patterns during DNA amplification, addressing a fundamental limitation of conventional PCR where epigenetic information is lost. The platform enables high-fidelity copying of both the methylation patterns and the four-base genetic code, supporting clinical applications in oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection. The technology supports both whole genome and targeted workflows, enabling genome-wide discovery and targeted follow-up studies.

Product and service1 record
1mcPCR™ (methyl-copying PCR) Platform
CategoryMolecular Diagnostics Platform
Description

A proprietary molecular biology platform technology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification using proprietary methyl transferase enzymes. Copies both epigenetic modifications and the underlying four-base genetic code, enabling high-fidelity methylation analysis from limiting clinical samples including liquid biopsies. Sold to clinical laboratories, healthcare providers, and research institutions for DNA methylation-based diagnostics and research applications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Undisclosed research groups
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Syndex Bio is collaborating with undisclosed research groups to advance the mcPCR technology for liquid biopsy applications.

genomeweb.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Qiagen offers sample-prep, PCR, and methylation-biomarker products (e.g., PyroMark for DNA methylation analysis). Comparable as an established supplier of methylation-analysis tools to clinical and research labs that could partner with, distribute, or compete with Syndex.

TypeBroad incumbent
Description

Natera offers Signatera (tumor-informed MRD) and a methylation-based colorectal screening assay. Comparable in pursuing methylation-aware clinical diagnostics for oncology; serves overlapping biopharma and clinical-lab customers.

TypeBroad incumbent
Description

Illumina is the dominant NGS platform vendor and now owns GRAIL, giving it both the sequencing infrastructure and methylation-diagnostics portfolio relevant to Syndex's downstream workflows. Comparable as the platform/ecosystem incumbent Syndex's enzyme technology would plug into.

TypeBroad incumbent
Description

GRAIL pioneered methylation-based multi-cancer early detection (Galleri) and is the most-cited competitor in Syndex's own market landscape. Comparable as a methylation-driven liquid biopsy developer; GRAIL operates at vastly larger scale and is now owned by Illumina.

TypeBroad incumbent
Description

Guardant is a leading liquid biopsy company with methylation-enabled products (e.g., Guardant Infinity, Reveal MRD). Directly comparable target market (oncology, MRD, drug development) and shared reliance on blood-based cfDNA workflows.

TypeBroad incumbent
Description

Thermo Fisher supplies PCR/qPCR instruments, methylation reagents, and clinical diagnostic platforms (e.g., Ion Torrent). Comparable as a broad life-science tools incumbent that could partner with or compete against Syndex for clinical-lab workflows.

7Epinoma
TypeEmerging player
Description

Epinoma is explicitly named in Syndex's own source data as a rival competing in early-stage liquid biopsy cancer detection. Comparable as a similarly early-stage, epigenetics-focused liquid biopsy developer pursuing the same beachhead market.

TypeEmerging player
Description

Singlera develops methylation-based liquid biopsy assays for early cancer detection (e.g., ColonES). Comparable as a methylation-driven diagnostics developer targeting similar clinical applications and customer segments.

TypeBroad incumbent
Description

Exact Sciences' Cologuard is the canonical commercial methylation-based diagnostic and demonstrates the clinical and commercial viability of methylation biomarkers in screening. Comparable in target customer (clinical labs, payors) and disease focus (early detection).

TypeEmerging player
Description

Bluestar developed 5-hydroxymethylcytosine-based liquid biopsy assays for early cancer detection (now part of Genentech/Roche). Comparable as an emerging methylation/epigenetic-based cancer detection company with a similar technology-to-product trajectory.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syndex Bio

Molecular Diagnosticssyndex.bio

Syndex Bio is a Cambridge, UK biotech startup developing mcPCR, a proprietary PCR-based platform that preserves DNA methylation patterns during amplification, targeting clinical laboratories and research institutions for applications in early cancer detection, liquid biopsy, and disease monitoring.

What Syndex Bio does

Syndex Bio is a Cambridge, UK-based biotechnology company founded in 2022 that has developed mcPCR (methyl-copying PCR), a proprietary platform technology designed to preserve 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. Conventional PCR cannot copy epigenetic methylation marks; mcPCR uses proprietary methyl transferase enzymes to copy both the four-base genetic code and methylation modifications on newly synthesised strands, enabling analysis from limiting clinical samples including liquid biopsies. The platform supports both whole-genome and targeted workflows with a non-destructive process intended to integrate into downstream genomic and multi-omic analyses. Target applications include oncology testing and early cancer detection, residual disease and treatment monitoring, drug development and patient stratification, and chronic disease detection.

The company operates a B2B go-to-market targeting clinical laboratories, healthcare providers, and research institutions. Revenue is expected to come from one-time licences of the mcPCR platform and reagents, supplemented by professional services tied to clinical workflow development. The company has 17 employees, no disclosed paying customers, and publicly undisclosed pricing. Its founding team includes individuals credited with inventing and commercialising next-generation sequencing (NGS) technology.

In February 2026 Syndex Bio publicly launched the mcPCR platform at the AGBT General Meeting in Orlando and concurrently closed a $15.5 million oversubscribed seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. Concurrent with the financing, the company formed a board of directors that includes Gautam Kollu, former Chief Commercial Officer of Grail, signalling intent to build an enterprise commercial motion in molecular diagnostics. Syndex Bio is collaborating with undisclosed research groups to advance liquid biopsy applications and plans to compete alongside rivals such as Epinoma in early-stage cancer detection.

Syndex Bio firmographics

Firmographics
Name
Syndex Bio
Legal name
Syndex Bio Limited
Website
https://syndex.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Syndex Bio is a Cambridge, UK biotech startup developing mcPCR, a proprietary PCR-based platform that preserves DNA methylation patterns during amplification, targeting clinical laboratories and research institutions for applications in early cancer detection, liquid biopsy, and disease monitoring.
Ownership category
akta.pro rank

Syndex Bio industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • DNA methylation analysis
  • Molecular diagnostics
  • PCR technology platform
  • Liquid biopsy reagents
  • Epigenetics research tools

Where Syndex Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Syndex Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. mcPCR platform and reagents: Revenue expected from selling mcPCR technology, reagents, and kits to clinical laboratories, healthcare providers, and research institutions for DNA methylation analysis applications including early cancer detection, disease monitoring, and clinical diagnostics.
  2. Clinical workflow development: Developing clinical workflows and applications that will enable deployment of mcPCR technology in healthcare settings for oncology testing, residual disease monitoring, drug development, and chronic disease detection.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Syndex Bio product offering

Product offering

Core offering

Syndex Bio develops and sells the proprietary mcPCR (methyl-copying PCR) platform, a biotechnology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. The platform enables high-fidelity copying of both epigenetic modifications and the underlying four-base genetic code, overcoming a fundamental 40-year limitation of conventional PCR. The company sells the technology along with reagents and kits to clinical laboratories, healthcare providers, and research institutions for applications including oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection.

Product overview

Syndex Bio offers a single unified product platform: the mcPCR™ (methyl-copying PCR) platform. This proprietary technology is designed to preserve DNA methylation (5mC) patterns during DNA amplification, addressing a fundamental limitation of conventional PCR where epigenetic information is lost. The platform enables high-fidelity copying of both the methylation patterns and the four-base genetic code, supporting clinical applications in oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection. The technology supports both whole genome and targeted workflows, enabling genome-wide discovery and targeted follow-up studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • mcPCR™ (methyl-copying PCR) Platform A proprietary molecular biology platform technology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification using proprietary methyl transferase enzymes. Copies both epigenetic modifications and the underlying four-base genetic code, enabling high-fidelity methylation analysis from limiting clinical samples including liquid biopsies. Sold to clinical laboratories, healthcare providers, and research institutions for DNA methylation-based diagnostics and research applications.

Quantifiable outcome

  • Earlier disease detection through sensitive methylation analysis from liquid biopsies
  • +2 more outcomes

Companies that use Syndex Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Syndex Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Syndex Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Undisclosed research groupsminorStrategic or Co-development Partner · 23 February 2026Syndex Bio is collaborating with undisclosed research groups to advance the mcPCR technology for liquid biopsy applications.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Syndex Bio competitors and assessment

Company assessment

Broad incumbents

  • Qiagen: Qiagen offers sample-prep, PCR, and methylation-biomarker products (e.g., PyroMark for DNA methylation analysis). Comparable as an established supplier of methylation-analysis tools to clinical and research labs that could partner with, distribute, or compete with Syndex.
  • Natera: Natera offers Signatera (tumor-informed MRD) and a methylation-based colorectal screening assay. Comparable in pursuing methylation-aware clinical diagnostics for oncology; serves overlapping biopharma and clinical-lab customers.
  • Illumina: Illumina is the dominant NGS platform vendor and now owns GRAIL, giving it both the sequencing infrastructure and methylation-diagnostics portfolio relevant to Syndex's downstream workflows. Comparable as the platform/ecosystem incumbent Syndex's enzyme technology would plug into.
  • GRAIL (Illumina): GRAIL pioneered methylation-based multi-cancer early detection (Galleri) and is the most-cited competitor in Syndex's own market landscape. Comparable as a methylation-driven liquid biopsy developer; GRAIL operates at vastly larger scale and is now owned by Illumina.
  • Guardant Health: Guardant is a leading liquid biopsy company with methylation-enabled products (e.g., Guardant Infinity, Reveal MRD). Directly comparable target market (oncology, MRD, drug development) and shared reliance on blood-based cfDNA workflows.
  • Thermo Fisher Scientific: Thermo Fisher supplies PCR/qPCR instruments, methylation reagents, and clinical diagnostic platforms (e.g., Ion Torrent). Comparable as a broad life-science tools incumbent that could partner with or compete against Syndex for clinical-lab workflows.
  • Exact Sciences: Exact Sciences' Cologuard is the canonical commercial methylation-based diagnostic and demonstrates the clinical and commercial viability of methylation biomarkers in screening. Comparable in target customer (clinical labs, payors) and disease focus (early detection).

Emerging players

  • Epinoma: Epinoma is explicitly named in Syndex's own source data as a rival competing in early-stage liquid biopsy cancer detection. Comparable as a similarly early-stage, epigenetics-focused liquid biopsy developer pursuing the same beachhead market.
  • Singlera Genomics: Singlera develops methylation-based liquid biopsy assays for early cancer detection (e.g., ColonES). Comparable as a methylation-driven diagnostics developer targeting similar clinical applications and customer segments.
  • Bluestar Genomics (Genentech): Bluestar developed 5-hydroxymethylcytosine-based liquid biopsy assays for early cancer detection (now part of Genentech/Roche). Comparable as an emerging methylation/epigenetic-based cancer detection company with a similar technology-to-product trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

Syndex Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syndex Bio leadership team

Management profile

Number of profiles

Profiles8 records

Syndex Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syndex Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syndex Bio

What does Syndex Bio do?

Syndex Bio develops and sells the proprietary mcPCR (methyl-copying PCR) platform, a biotechnology that preserves 5-methylcytosine (5mC) DNA methylation patterns during DNA amplification. The platform enables high-fidelity copying of both epigenetic modifications and the underlying four-base genetic code, overcoming a fundamental 40-year limitation of conventional PCR. The company sells the technology along with reagents and kits to clinical laboratories, healthcare providers, and research institutions for applications including oncology testing, early cancer detection, residual disease monitoring, drug development, patient stratification, and chronic disease detection.

Is Syndex Bio a public or private company?

Syndex Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Syndex Bio founded?

Syndex Bio was founded in 2022. It employs 11 to 50 people.

Where is Syndex Bio based?

Syndex Bio is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Syndex Bio make money?

Two revenue lines are on record. mcPCR platform and reagents are the primary driver. The others are clinical workflow development.

Who are Syndex Bio's main competitors?

Broad incumbents on record are Qiagen, Natera, Illumina, GRAIL (Illumina), Guardant Health, Thermo Fisher Scientific and Exact Sciences. Emerging players are Epinoma, Singlera Genomics and Bluestar Genomics (Genentech).

Does Syndex Bio have an API?

No public API is recorded for Syndex Bio.

What industry is Syndex Bio in?

Syndex Bio's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magSyndex Bio Debuts Proprietary mcPCR TechnologySyndex Bio has launched its proprietary mcPCR platform, a technology that enables the high-fidelity amplification of DNA methylation patterns for improved disease detection. The company simultaneously closed an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners to support R&D expansion in the U.K.EIN PresswirePredictive Genetic Testing and Consumer/Wellness Genomics Market Size to Surpass USD 12.24 Billion by 2032The Predictive Genetic Testing and Consumer/Wellness Genomics market was valued at USD 5.4 billion in 2025 and is projected to reach USD 12.24 billion by 2032, growing at a CAGR of 12.4%, driven by rising consumer awareness, direct-to-consumer testing adoption, and AI-driven genomic insights. Key developments include Syndex Bio's launch of the mcPCR Platform (February 2026), Myriad Genetics' expansion of its Foresight Carrier Screen (October 2025), Roche's sequencing system roadmap (August 2025), and Illumina's Japanese regulatory approval and Tempus partnership (May/April 2025). North America leads the market in adoption while Asia-Pacific and Latin America are emerging as high-growth regions.BiotechniquesThe biotech bi-weekly: analyzing methylated DNA, accelerating rare disease research with global data and moreThe article serves as a newsletter summary highlighting key biotech industry announcements, including Syndex Bio's introduction of a platform for methylated DNA analysis. It also mentions an upcoming cloud-based computational platform for metabolomics data and the efficacy of therapeutic antibodies using a mouse model. The text further promotes registration for the ABRF 2026 Annual Meeting in Pittsburgh.Longevity.TechnologySyndex Bio’s mcPCR opens new path for early disease detectionUK-based biotech Syndex Bio unveiled its mcPCR (methyl-copying PCR) platform at AGBT 2026 in Orlando, a technology designed to copy DNA alongside its methylation patterns, enabling more sensitive detection of disease markers from small or non-invasive samples such as liquid biopsies. The company simultaneously closed a $15.5 million oversubscribed seed funding round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures and Meltwind, which will support platform expansion and R&D operations in Cambridge, UK. The technology addresses a long-standing limitation of traditional PCR by preserving epigenetic information during amplification, potentially enabling earlier disease detection and more accurate cancer screening.InsidermediaSyndex Bio unveils new mcPCR platform following £11.5m seed roundSyndex Bio, a Cambridge-based biotech firm, introduced its mcPCR platform for DNA methylation analysis after raising £11.5m in a seed round. The platform aims to improve early disease detection and recurrence monitoring by enabling sensitive analysis of methylated DNA.European BiotechnologySyndex Bio raises $15.5M seed and unveils mcPCR platform for DNA methylation analysisCambridge, UK-based Syndex Bio announced the launch of its proprietary mcPCR™ (methyl-copying PCR) platform for DNA methylation analysis and the close of a $15.5 million oversubscribed seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures and Meltwind Advisory LLP. The mcPCR platform enables precise copying of both DNA methylation marks and the four-base genetic code during amplification, addressing what the company describes as a fundamental limitation of conventional PCR where epigenetic modifications are not preserved. The funds will support expansion of the mcPCR platform, development of clinical workflows and applications, and R&D growth in Cambridge, UK, with Gautam Kollu, former Chief Commercial Officer of Grail, joining the company's Board of Directors.SyndexSyndex Bio Unveils mcPCR Technology at AGBT 2026 Following $15.5M Seed Financing — Syndex BioSyndex Bio announced the launch of its proprietary mcPCR (methyl-copying PCR) platform at the AGBT Conference in Orlando, Florida, alongside the successful close of a $15.5 million seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. The mcPCR technology enables high-fidelity copying of DNA methylation patterns during DNA amplification, overcoming a fundamental limitation of standard PCR that cannot replicate methylation information critical for disease detection. The company also announced the appointment of Gautam Kollu, former Chief Commercial Officer of Grail, to its newly formed Board of Directors, and the funds will support platform expansion, clinical workflow development, and R&D operations in Cambridge, UK.GenomeWebSyndex Bio Nabs $15.5M Seed Funding to Develop Methylation-Preserving PCR TechSyndex Bio, a UK-based startup, has raised $15.5 million in seed funding led by Arch Venture Partners to develop its methylation-preserving PCR (mcPCR) technology, which addresses a long-standing technical barrier in epigenetics by preserving 5-methylcytosine patterns during DNA amplification. The funding will support platform development, clinical workflow creation, and R&D, with the company planning to compete in the liquid biopsy market for early-stage cancer detection alongside rival Epinoma. Founded in 2022 and headquartered in Cambridge, Syndex Bio has grown to 17 employees and is collaborating with undisclosed research groups to advance the technology.News-MedicalSyndex Bio unveils mcPCR technology at AGBT 2026 following $15.5 M seed financingSyndex Bio unveiled its mcPCR platform at AGBT 2026, enabling PCR amplification of DNA methylation. The company closed a $15.5 million seed round led by ARCH Venture Partners, with funds for platform expansion and R&D in Cambridge, UK. Founder Geoff Smith will present a poster on the technology at the conference.Business WeeklyFlorida key as Syndex Bio follows $15.5m seed round with DNA product launchSyndex Bio, a Cambridge-based biotech company, has launched its mcPCR platform that enables high-fidelity copying of DNA methylation patterns during DNA amplification, overcoming a fundamental limitation of conventional PCR for early disease detection and recurrence monitoring. The company simultaneously announced the close of an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners with participation from +ND Capital, OMX Ventures and Meltwind, which will fund expansion of the platform, development of clinical workflows, and R&D growth in the Cambridge Cluster. Gautam Kollu, former Chief Commercial Officer of Grail, has joined the company's newly formed Board of Directors alongside existing members.